Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 14/20 | 0.51 |
| ▸ | PDE4A | P27815 | 4/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31492425 | 0.97 | PGR (0.51) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31492452 | 0.94 | PGR (0.49) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30446355 | 0.88 | BACE1 (0.47) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25399999 | 0.79 | PGR (0.58) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29609794 | 0.79 | PGR (0.58) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12056346 | 0.78 | PGR (0.49) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4715658 | 0.78 | PGR (0.59) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5959182 | 0.76 | EPHX2 (0.51) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30445918 | 0.76 | BACE1 (0.47) | TDP2 | |
| SCHEMBL20269069 | 0.76 | PGR (0.55) | PGRPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| EP-3107910-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015124868-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | PGR 463/4885PDE4A 1557/4885PDE4B 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.